ADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019 Joined CoVIg-19

ADMA Biologics Reports Business Highlights

and Second Quarter 2020 Financial Results

Generated Total Revenues of $18.0 Million

for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019

Joined CoVIg-19 Plasma Alliance and Successfully

Opened New ADMA BioCenters Plasma Collection Center

Company Anticipates Generating $250 Million

or More in Annual Revenues Within Next Three to Five Calendar Years

Management to Host Conference Call and

Webcast Today at 4:30 p.m. ET

RAMSEY, NJ and BOCA RATON, FL - August 5, 2020

- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated

to manufacturing, marketing and developing specialty plasma-derived biologics, today reported business highlights and financial

results for its fiscal second quarter and six months ended June 30, 2020, and provided an overview of recent progress and accomplishments.

"The first half of 2020 was marked by several achievements

and challenges as we navigate through these unprecedented macro-market conditions," said Adam Grossman, President and Chief

Executive Officer of ADMA. "Total revenues for the first half of 2020 increased approximately 78% compared to the same prior

year period. While the second quarter 2020 revenues were approximately 19% higher than second quarter 2019 revenues, ADMA, and

certain of its third-party vendors, experienced impacts from the global COVID-19 pandemic which resulted in unforeseen supply chain

disruptions. These COVID-19 disruptions were primarily related to delays with final product Current Good Manufacturing Practice

("cGMP") release testing by third-party vendors. This means that a few of our production batches were finished on schedule

but we were unable to submit for U.S. Food and Drug Administration ("FDA") lot release authorization due to delayed

These delays were mainly experienced during the latter part

of the second quarter and have since been resolved during July. In response to these delays, and in partnership with the FDA, we

added additional release testing laboratories to our approved consortium and believe we have completely resolved the issue and

do not anticipate additional testing or batch release delays going forward.

Market demand for our immunoglobulin product portfolio remains

strong and we anticipate considerable revenue growth for the second half of the year and are excited for the anticipated production

volume increases from our capacity expansion efforts in 2021 and beyond. We also believe we remain on track to achieve

our stated goal of generating $250 million or more in annual revenues within the next three to five calendar years."

"In accordance with our stated corporate objectives, during

the quarter we completed construction of a new plasma collection center, initiated donor collections and submitted a Biologics

License Application ("BLA") to the FDA, with an approval decision expected in mid-2021. We also installed

and qualified a new aseptic fill-finish machine at our Boca Raton facility, and manufactured conformance batches of BIVIGAM

at an increased scale that will ultimately allow us to manufacture at twice the volume as the process that is in place today. And

finally, we joined the CoVIg-19 Plasma Alliance and began collection of plasma from COVID-19 convalesced patients. We are proud

of these important achievements and milestones and believe we have set the stage to now be in a position to ensure the U.S. market

has a continuous supply of BIVIGAM , ASCENIV and NABI-HB . We are on target for positioning our operations to capitalize

on the continued forecasted growth of the plasma products industry. Our production throughput and finished product supply remains

on track to begin realizing the benefits from these initiatives as early as mid-2021," concluded Mr. Grossman.

Second Quarter 2020 Highlights and Recent Events

Financial Results for the Three Months Ended June 30, 2020

Total revenues for the quarter ended June 30, 2020 were $7.8

million, compared to $6.6 million for the quarter ended June 30, 2019, representing an increase of approximately $1.2 million,

or approximately 19%. The increase is primarily due to sales of BIVIGAM, ASCENIV and intermediates, compared to no sales from these

products during the same prior year period. ADMA's revenues for the second quarter of 2020, compared to the second quarter

of 2019, were favorably impacted by the FDA approvals of BIVIGAM and ASCENIV on May 9, 2019 and April 1, 2019, respectively, and

by the manufacturing and supply agreement ADMA entered into in January 2020 to produce and sell intermediate fractions to a certain

Consolidated net loss for the quarter ended June 30, 2020 was

$20.2 million, or $(0.23) per basic and diluted share, compared to a consolidated net loss of $13.2 million, or $(0.25) per basic

and diluted share, for the quarter ended June 30, 2019. The increase in net loss of $7.0 million was primarily due to increased

cost of product revenue of $3.0 million related to sales of FDA-approved immunoglobulin products not present in the same prior

year period, along with the remaining costs associated with the manufacturing of BIVIGAM's increased plasma pool conformance

lots as part of our planned capacity expansion, partially offset by a decrease in unabsorbed manufacturing expense at the Boca

Raton, FL production facility. The increase in net loss during the second quarter of 2020 is also attributable to higher research

and development expenses of $1.1 million, largely due to costs associated with the testing and development of a new filling line

at one of our third-party fill finishers, and to increased selling, general and administrative expenses of $2.6 million,

mainly due to increases in employee compensation expenses and other costs in support of our commercialization efforts for BIVIGAM

and ASCENIV. In addition, interest expense for the quarter increased by $1.0 million due to our accessing additional debt during

the second quarter of 2019 and first quarter of 2020. Included in the net loss for the second quarter of 2020 were non-cash expenses

of approximately $2.0 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.

Financial Results for the Six Months Ended June 30, 2020

Total revenues for the six months ended June 30, 2020 were $18.0

million, compared to $10.1 million for the six months ended June 30, 2019, representing an increase of $7.9 million, or approximately

78%. The increase in revenues was primarily attributable to sales of BIVIGAM, ASCENIV and intermediates, compared to no sales from

these products during the same prior year period.

Consolidated net loss for the six months ended June 30, 2020

was $39.4 million, or $(0.49) per basic and diluted share, compared to a consolidated net loss of $26.3 million, or $(0.53) per

basic and diluted share, for the six months ended June 30, 2019. The increase in net loss of $13.1 million was primarily attributable

to increased cost of product revenue of $10.4 million related to sales of BIVIGAM, ASCENIV and intermediates not present during

the first half of 2019, along with the costs associated with the manufacturing of BIVIGAM's increased plasma pool

conformance lots as part of our planned capacity expansion, along with other production initiatives and investments at the Boca

Raton facility. Other factors contributing to the increase in net loss include: higher research and development expenses attributed

to costs associated with testing and development of a new fill line at our third-party fill finisher and costs incurred for a study

we commenced to potentially extend ASCENIV's approved and labeled expiration dating, higher selling, general administrative

expenses in support of our commercialization efforts of BIVIGAM's relaunch and ASCENIV's launch and the overall growth

in the size and scope of the Company's operations along with higher interest expense due to accessing additional debt during

the second quarter of 2019 and first quarter of 2020. Included in the net loss for the first half of 2020 were non-cash expenses

of approximately $3.9 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.

At June 30, 2020, ADMA had cash and cash equivalents of $75.8

million and accounts receivable of $6.5 million, compared to cash and cash equivalents of $26.8 million and accounts receivable

of $3.5 million at December 31, 2019. ADMA's net working capital as of June 30, 2020 was $130.1 million, compared to $71.8

million as of December 31, 2019.

Conference Call Information

ADMA will host a conference call today, Wednesday, August 5,

2020, at 4:30 p.m. Eastern Time, to discuss the second quarter 2020 financial results and recent corporate updates. To access the

conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time

and refer to conference ID 8992308. A live audio webcast of the call will be available under "Events & Webcasts"

in the Investor section of the Company's website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available

on the Company's website approximately two hours after the event.

BIVIGAM (immune globulin intravenous, human - 10% liquid)

is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated

for the treatment of primary humoral immunodeficiency (PI), including, but not limited to the following group of genetic disorders:

X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency.

BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against

bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation

of concentrated human Immunoglobulin (IgG) antibodies.

ASCENIV (immune globulin intravenous, human - slra 10%

liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the FDA on April 1, 2019 and

is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD),